Hypogammaglobulinemia in Multiple Sclerosis Patients Receiving Disease-Modifying Immunomodulatory Agents

被引：0
|
作者：
Tsao, Lulu [1 ]
Otani, Iris M. [2 ]
Bove, Riley [3 ]
机构：
[1] UCSF, Dept Med, San Francisco, CA USA
[2] UCSF, Dept Internal Med, Div Allergy & Immunol, San Francisco, CA USA
[3] UCSF, Dept Neurol, San Francisco, CA USA
来源：
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY | 2019年 / 143卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
49
引用
收藏
页码：AB17 / AB17
页数：1
相关论文
共 50 条
  • [21] Disease-Modifying Agents for Multiple Sclerosis Recent Advances and Future Prospects
    Menge, Til
    Weber, Martin S.
    Hemmer, Bernhard
    Kieseier, Bernd C.
    von Buedingen, Hans-Christian
    Warnke, Clemens
    Zamvil, Scott S.
    Boster, Aaron
    Khan, Omar
    Hartung, Hans-Peter
    Stuve, Olaf
    [J]. DRUGS, 2008, 68 (17) : 2445 - 2468
  • [22] Outcome of COVID-19 infection in multiple sclerosis patients receiving disease-modifying therapies
    Etemadifar, Masoud
    Sami, Ramin
    Salari, Mehri
    Sedaghat, Nahad
    Sigari, Amirhossein Akhavan
    Aghababaei, Ali
    Najafi, Mohammadreza
    Tehrani, Donya Sheibani
    [J]. JOURNAL OF RESEARCH IN MEDICAL SCIENCES, 2021, 26 (01):
  • [23] Disease-modifying agents in the Sonya Slifka Longitudinal Multiple Sclerosis Study
    Minden, S.
    Hoaglin, D.
    Jureidini, S.
    Hadden, L.
    Frankel, D.
    Komatsuzaki, Y.
    Outley, J.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2008, 14 (05) : 640 - 655
  • [24] Disease-modifying therapies for multiple sclerosis
    John R. Corboy
    Douglas S. Goodin
    Elliot M. Frohman
    [J]. Current Treatment Options in Neurology, 2003, 5 (1) : 35 - 54
  • [25] Measuring adherence and persistence to disease-modifying agents among patients with relapsing remitting multiple sclerosis
    Lafata, Jennifer Elston
    Cerghet, Mirela
    Dobie, Elizabeth
    Schultz, Lonni
    Tunceli, Kaan
    Reuther, Jacqueline
    Elias, Stanton
    [J]. JOURNAL OF THE AMERICAN PHARMACISTS ASSOCIATION, 2008, 48 (06) : 752 - 757
  • [26] Adherence to Disease-Modifying Agents among Patients with Multiple Sclerosis: 5 Year Prospective Study
    Cerghet, Mirela
    Elias, Stanton
    Dobie, Liz
    Salloum, Ramzi
    Elston-Lafata, Jennifer
    Schultz, Lonni
    [J]. NEUROLOGY, 2011, 76 (09) : A72 - A73
  • [27] FIRST USE OF DISEASE-MODIFYING DRUGS IN PATIENTS WITH MULTIPLE SCLEROSIS
    Meletiche, D. M.
    Kozma, C.
    Dickson, M.
    [J]. VALUE IN HEALTH, 2009, 12 (03) : A193 - A193
  • [28] Infections in patients with multiple sclerosis: Implications for disease-modifying therapy
    Celius, E. G.
    [J]. ACTA NEUROLOGICA SCANDINAVICA, 2017, 136 : 34 - 36
  • [29] Adherence to disease-modifying treatments in patients with multiple sclerosis in Spain
    Morillo Verdugo, Ramon
    Ramirez Herraiz, Esther
    Fernandez-Del Olmo, Raquel
    Roig Bonet, Montserrat
    Valdivia Garcia, Maria
    [J]. PATIENT PREFERENCE AND ADHERENCE, 2019, 13 : 261 - 272
  • [30] Persistence to oral disease-modifying therapies in multiple sclerosis patients
    Simona Lattanzi
    Maura Danni
    Ruja Taffi
    Raffaella Cerqua
    Giulia Carlini
    Alessandra Pulcini
    Leandro Provinciali
    Mauro Silvestrini
    [J]. Journal of Neurology, 2017, 264 : 2325 - 2329
12345